Early lung cancer test gains R&D (research and development) grant:
This article was originally published in Clinica
Executive Summary
Canada's DiagnoCure and Israel's Compugen have received a cash boost to support their joint project to develop a nucleic acid probe-based diagnostic kit for the early detection of lung cancer. The Canada-Israel Industrial Research and Development Foundation, which promotes collaborative R&D between firms in both countries, has awarded the firms Can $800,000 ($502,000). The lung cancer test will combine Tel Aviv-based Compugen's capabilities in identifying novel disease markers and predicting their utility with Quebec City based DiagnoCure's expertise in developing, manufacturing and commercialising molecular diagnostic assays. Lung cancer is the leading cause of cancer death worldwide, says DiagnoCure. About 1.3 million cases of lung cancer are diagnosed each year. In the US alone, it is estimated that more than 170,000 individuals were diagnosed with lung cancer and 158,000 died from the disease in 2001.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.